Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy

Endocrine-Related Cancer

Volumn 12, Issue SUPPL. 1, 2005, Pages

  Bianco, Roberto ^a   Troiani, Teresa ^b   Tortora, Giampaolo ^a   Ciardiello, Fortunato ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; BASIC FIBROBLAST GROWTH FACTOR; CANERTINIB; CETUXIMAB; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GLYCOPROTEIN P; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT5 PROTEIN; TAMOXIFEN; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; AUTOCRINE EFFECT; BREAST CANCER; CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONFERENCE PAPER; DRUG EFFICACY; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LUNG METASTASIS; METASTASIS; MOLECULAR WEIGHT; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 25844481618     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00999     Document Type: Conference Paper

References (86)

1. Ali IU, Schriml LM & Dean M 1999 Mutational spectra of PTEN/MMAC1 gene a tumor suppressor with lipid phosphatase activity. Journal of the National Cancer Institute 17 1922-1932.
2. Amador ML, Oppenheimer D, Perea S, Maitra A, Cusati G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A & Hidalgo M 2004 An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Research 15 9139-9143.
3. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N & Nishio K 2004 Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Research 15 9101-9104.
4. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P & Kerwin R 1995 Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346 281-282.
5. Arteaga CL 2002 Epidermal growth factor receptor dependence in human tumors more than just expression? Oncologist 7 (Suppl 4) 31-39.
6. Arteaga CL & Baselga J 2003 Clinical trial design and end points for epidermal growth factor receptor-targeted therapies implications for drug development and practice. Clinical Cancer Research 9 1579-1589.
7. Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A, Groner B & Wels W 2000 Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. International Journal of Cancer 15 269-275.
8. Barber TD, Vogelstein B, Kinzler KW & Velculescu VE 2004 Somatic mutations in colorectal cancer and glioblastomas. New England Journal of Medicine 351 2883.
9. Baselga J, Norton L, Albanell J, Kim YM & Mendelsohn J 1998 Recombinant humanized anti-receptor-expressingHER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Research 58 2825-2831.
10. Benetos A, Cambien F, Gautier S, Ricard S, Safar M, Laurent S, Lacolley P, Poirier O, Topouchian J & Asmar R 1996 Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 28 1081-1084.
11. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB & Arteaga CL 2003 Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 8 2812-2822.
12. Bishop PC, Myers T, Robey R, Fry DW, Liu ET, Blagosklonny MV & Bates SE 2002 Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 3 119-127.
13. Blencke S, Ullrich A & Daub H 2003 Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. The Journal of Biological Chemistry 25 15435-15440.
14. Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ, Morgan GJ, Hughes CJ & Sutherland RL 1999 Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clinical Cancer Research 5 2810-2819.
15. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, Simon R, Lelle R, Boecker W & Brandt B 2000 Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Research 60 854-857.
16. Busse D, Doughty RS & Arteaga CL 2001 HER-2/neu (erbB-2) and the cell cycle. Seminars in Oncology 27 (Suppl 11) 3-8.
17. Chakravarti A, Loeffler JS & Dyson NJ 2002 Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Research 1 200-207.
18. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH & Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 23 563-566.
19. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN & Testa JR 1992 AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. PNAS 1 9267-9271.
20. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK & Testa JR 1996 Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. PNAS 16 3636-3641.
21. Chrysogelos SA 1993 Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells. Nucleic Acids Research 21 5736-5741.
22. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR & Tortora G 1996 Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. Journal of the National Cancer Institute 4 1770-1776.
23. Ciardiello F & Tortora G 2001 A novel approach in the treatment of cancer targeting the epidermal growth factor receptor. Clinical Cancer Research 7 2958-2970.
24. Ciardiello F, Caputo R, Troiani T, Borriello G, Kandimalla ER, Agrawal S, Mendelsohn J, Bianco AR & Tortora G 2001a Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. International Journal of Cancer 15 172-178.
25. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR & Tortora G 2001b Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical Cancer Research 7 1459-1465.
26. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR & Tortora G 2004 Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clinical Cancer Research 15 784-793.
27. Clynes RA, Towers TL, Presta LG & Ravetch JV 2000 Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine 6 443-446.
28. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC & Kaufmann SH 2001 The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10- hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Research 15 739-748.
29. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, Milchgrub S, Brezinschek R, Virmani A, Gazdar AF & Minna JD 1998 Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 24 1557-1565.
30. Gebhardt F, Zanker KS & Brandt B 1999 Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. The Journal of Biological Chemistry 274 13176-13180.
31. Gille J, Swerlick RA & Caughman SW 1997 Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 17 750-759.
32. Goldman CK, Kim J, Wong WL, King V, Brock T & Gillespie GY 1993 Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells a model of glioblastoma multiforme pathophysiology. Molecular Biology of the Cell 4 121-133.
33. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD & Tweardy DJ 1998 Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. Journal of the National Cancer Institute 90 824-832.
34. Henrion D, Amant C, Benessiano J, Philip I, Plantefeve G, Chatel D, Hwas U, Desmont JM, Durand G, Amouyel P & Levy BI 1998 Angiotensin II type 1 receptor gene polymorphism is associated with an increased vascular reactivity in the human mammary artery in vitro. Journal of Vascular Research 35 356-362.
35. Holly JM 1998 Insulin-like growth factor-I and new opportunities for cancer prevention. Lancet 351 1373-1375.
36. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR & Tsai SF 2004 High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clinical Cancer Research 15 8195-8203.
37. Hulit J, Lee RJ, Russell RG & Pestell RG 2002 ErbB-2-induced mammary tumor growth: the role of cyclin D1 and p27Kip1. Biochemical Pharmacology 64 827-836.
38. Jares P, Fernandez PL, Campo E, Nadal A, Bosch F, Aiza G, Nayach I, Traserra J & Cardesa A 1994 PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Research 1 4813-4817.
39. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE & Nicholson RI 2004 Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 11 793-814.
40. Kalish LH, Kwong RA, Cole IE, Gallagher RM, Sutherland RL & Musgrove EA 2004 Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clinical Cancer Research 15 7764-7774.
41. Kuan CT, Wikstrand CJ & Bigner DD 2001 EGF mutant receptor vIII as a molecular target in cancer therapy. Endocrine-Related Cancer 8 83-96.
42. Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD & Sampson JH 2004 Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clinical Cancer Research 1 3216-3224.
43. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ & Lee SH 2005 Absence of EGFR mutations in the kinase domain in common human cancers beside non-small cell lung cancer. International Journal of Cancer 113 510-511.
44. Lenferink AE, Busse D, Flanagan WM, Yakes FM & Arteaga CL 2001 ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Research 1 6583-6591.
45. Lengauer C, Kinzler KW & Vogelstein B 1998 Genetic instabilities in human cancers. Nature 396 643-649.
46. LeRoith D, Werner H, Beitner-Johnson D & Roberts CT Jr 1995 Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Reviews 16 143-163.
47. Li B, Chang CM, Yuan M, McKenna WG & Shu HK 2003 Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Research 1 7443-7450.
48. Li DM & Sun H 1998 PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. PNAS 22 15406-15411.
49. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH & Johnson JA 1999 Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clinical Pharmacology and Therapeutics 65 519-525.
50. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K & Mills GB 1999 The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 25 7034-45.
51. Lu Y, Zi X & Pollak M 2004 Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. International Journal of Cancer 20 334-341.
52. Lu Y, Zi X, Zhao Y, Mascarenhas D & Pollak M 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute 19 1852-1857.
53. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J & Haber DA 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 20 2129-2139.
54. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK & Shen CY 2000 PIK3CA as an oncogene in cervical cancer. Oncogene 25 2739-2544.
55. Mendelsohn J 2001 The epidermal growth factor receptor as a target for cancer therapy. Endorine-Related Cancer 8 3-9.
56. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL & Wong AJ 1995 Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Research 1 5536-5539.
57. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC & Yu D 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 117-127.
58. Nicholson RI, Gee JM & Harper ME 2001 EGFR and cancer prognosis. European Journal of Cancer 37 (Suppl 4) 9-15.
59. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL & Pollak M 2001 In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Research 61 6276-6280.
60. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK & Huang HJ 1994 A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. PNAS 2 7727-7731.
61. Nowell PC 1976 The clonal evolution of tumor cell populations. Science 194 23-28.
62. Okami K, Reed AL, Cairns P, Koch WM, Westra WH, Wehage S, Jen J & Sidransky D 1999 Cyclin D1 amplification is independent of pi6 inactivation in head and neck squamous cell carcinoma. Oncogene 10 3541-3545.
63. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE & Meyerson M 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 4 1497-500.
64. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M & Varmus H 2004 EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. PNAS 7 13306-13311.
65. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B & Kerbel RS 1997 Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo Angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology 151 1523-1530.
66. Pietras RJ, Pegram MD, Finn RS, Maneval DA & Slamon DJ 1998 Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17 2235-2249.
67. Resnicoff M & Baserga R 1998 The role of the insulin-like growth factor I receptor in transformation and apoptosis. Annals of the New York Academy of Sciences 842 76-81.
68. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, Fenaux P & Preudhomme C 2002 Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100 1014-1018.
69. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL & Van Etten RA 2002 Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. PNAS 6 10700-10705.
70. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J & Dmitrovsky E 1993 Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Research 15 (Suppl 10) 2379-2385.
71. Salomon DS, Brandt R, Ciardiello F & Normanno N 1995 Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology I Hematology 19 183-232.
72. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB & Gray JW 1999 PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics 21 99-102.
73. She QB, Solit D, Basso A & Moasser MM 2003 Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clinical Cancer Research 1 4340-4346.
74. Skvortsov S, Sarg B, Loeffler-Ragg J, Skvortsova I, Lindner H, Werner Ott H, Lukas P, Illmensee K & Zwierzina H 2004 Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. Molecular Cancer Therapeutics 3 1551-1558.
75. Sordella R, Bell DW, Haber DA & Settleman J 2004 Gefitinib- sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 20 1163-1167.
76. Stamos J, Sliwkowski MX & Eigenbrot C 2002 Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. The Journal of Biological Chemistry 29 46265-46272.
77. Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N & Nishio K 2004 Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ('Iressa')-sensitive and resistant xenograft models. Cancer Science 1 984-989.
78. van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ & de Jong PE 1996 Association between angiotensin converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 347 94-95.
79. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J & Kerbel RS 2001 Acquired resistance to the antitumor effect of epidermal growth factor receptor blocking antibodies in vivo A role for altered tumor angiogenesis. Cancer Research 61 5090-5101.
80. Viloria-Petit AM & Kerbel RS 2004 Acquired resistance to EGFR inhibitors mechanisms and prevention strategies. International Journal of Radiation Oncology Biology Physics 1 914-926.
81. Vivanco I & Sawyers CL 2002 The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews Cancer 2489-501.
82. Wells A 1999 EGF receptor. The International Journal of Biochemistry and Cell Biology 31 637-643.
83. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S & Arteaga CL 2002 Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Research 15 4132-4141.
84. Yamazaki H, Kijima H, Ohnishi Y, Abe Y, Oshika Y, Tsuchida T, Tokunaga T, Tsugu A, Ueyama Y, Tamaoki N & Nakamura M 1998 Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. Journal of the National Cancer Institute 15 581-587.
85. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I & Sakai O 1995 Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. The Journal of Clinical Investigation 96 2162-2169.
86. Yu H & Rohan T 2000 Role of the insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 92 1472-1489.